These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19447868)

  • 1. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
    Hanrahan EO; Ryan AJ; Mann H; Kennedy SJ; Langmuir P; Natale RB; Herbst RS; Johnson BE; Heymach JV
    Clin Cancer Res; 2009 May; 15(10):3600-9. PubMed ID: 19447868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
    Morabito A; Piccirillo MC; Falasconi F; De Feo G; Del Giudice A; Bryce J; Di Maio M; De Maio E; Normanno N; Perrone F
    Oncologist; 2009 Apr; 14(4):378-90. PubMed ID: 19349511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
    Heymach JV; Paz-Ares L; De Braud F; Sebastian M; Stewart DJ; Eberhardt WE; Ranade AA; Cohen G; Trigo JM; Sandler AB; Bonomi PD; Herbst RS; Krebs AD; Vasselli J; Johnson BE
    J Clin Oncol; 2008 Nov; 26(33):5407-15. PubMed ID: 18936474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
    Herbst RS; Sun Y; Eberhardt WE; Germonpré P; Saijo N; Zhou C; Wang J; Li L; Kabbinavar F; Ichinose Y; Qin S; Zhang L; Biesma B; Heymach JV; Langmuir P; Kennedy SJ; Tada H; Johnson BE
    Lancet Oncol; 2010 Jul; 11(7):619-26. PubMed ID: 20570559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
    Hanrahan EO; Heymach JV
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4617-22. PubMed ID: 17671152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.
    Natale RB; Bodkin D; Govindan R; Sleckman BG; Rizvi NA; Capó A; Germonpré P; Eberhardt WE; Stockman PK; Kennedy SJ; Ranson M
    J Clin Oncol; 2009 May; 27(15):2523-9. PubMed ID: 19332730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
    J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.
    Heymach JV; Lockwood SJ; Herbst RS; Johnson BE; Ryan AJ
    Ann Oncol; 2014 Oct; 25(10):1941-1948. PubMed ID: 25057173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.
    Heymach JV; Johnson BE; Prager D; Csada E; Roubec J; Pesek M; Spásová I; Belani CP; Bodrogi I; Gadgeel S; Kennedy SJ; Hou J; Herbst RS
    J Clin Oncol; 2007 Sep; 25(27):4270-7. PubMed ID: 17878479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
    Hanrahan EO; Lin HY; Kim ES; Yan S; Du DZ; McKee KS; Tran HT; Lee JJ; Ryan AJ; Langmuir P; Johnson BE; Heymach JV
    J Clin Oncol; 2010 Jan; 28(2):193-201. PubMed ID: 19949019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).
    Mok T; Gorbunova V; Juhasz E; Szima B; Burdaeva O; Orlov S; Yu CJ; Archer V; Hilton M; Delmar P; Pallaud C; Reck M
    J Thorac Oncol; 2014 Jun; 9(6):848-55. PubMed ID: 24807156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy plus Vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials.
    Xiao YY; Zhan P; Yuan DM; Liu HB; Lv TF; Shi Y; Song Y
    Clin Oncol (R Coll Radiol); 2013 Jan; 25(1):e7-e15. PubMed ID: 23177099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials.
    Qi WX; Tang LN; He AN; Shen Z; Yao Y
    Lung; 2011 Dec; 189(6):437-43. PubMed ID: 21986852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.
    Tsao AS; Liu S; Lee JJ; Alden CM; Blumenschein GR; Herbst R; Davis SE; Kim E; Lippman S; Heymach J; Tran H; Tang X; Wistuba I; Hong WK
    J Thorac Oncol; 2013 May; 8(5):658-61. PubMed ID: 23584298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
    de Boer RH; Arrieta Ó; Yang CH; Gottfried M; Chan V; Raats J; de Marinis F; Abratt RP; Wolf J; Blackhall FH; Langmuir P; Milenkova T; Read J; Vansteenkiste JF
    J Clin Oncol; 2011 Mar; 29(8):1067-74. PubMed ID: 21282537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vandetanib: An overview of its clinical development in NSCLC and other tumors.
    Morabito A; Piccirillo MC; Costanzo R; Sandomenico C; Carillio G; Daniele G; Giordano P; Bryce J; Carotenuto P; La Rocca A; Di Maio M; Normanno N; Rocco G; Perrone F
    Drugs Today (Barc); 2010 Sep; 46(9):683-98. PubMed ID: 20967300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Zhang X; Qin Y; Li H; Bai C; Zhu T; Xu J; Wu C; Wu M; Wang C; Song H; Wei L; He J
    Asian Pac J Cancer Prev; 2011; 12(11):2857-63. PubMed ID: 22393954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
    Lee JS; Hirsh V; Park K; Qin S; Blajman CR; Perng RP; Chen YM; Emerson L; Langmuir P; Manegold C
    J Clin Oncol; 2012 Apr; 30(10):1114-21. PubMed ID: 22370318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.
    Goto K; Ichinose Y; Ohe Y; Yamamoto N; Negoro S; Nishio K; Itoh Y; Jiang H; Duffield E; McCormack R; Saijo N; Mok T; Fukuoka M
    J Thorac Oncol; 2012 Jan; 7(1):115-21. PubMed ID: 21900837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.